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Abstract 
Introduction: Although circadian variation of (motor) symptoms in Parkinson disease (PD) 
patients has been described, it remains unclear what effect seasonal variation may have on 
non-motor symptoms (NMS).  
Methods: Cross-sectional retrospective study on 372 consecutive PD patients taking part in 
the Non-motor Longitudinal International Study at King’s College Hospital London between 
November 2011 and July 2018. Patients were divided into three groups based on their date of 
assessment, using a simplified seasonal model: group 1: November-February (n=107); group 
2: March-15 June (n=107); and group 3: 16 June-October (n=158). Primary outcome was a 
seasonal difference in NMS scale (NMSS) total scores (higher scores reflecting greater 
disability). We hypothesized that PD patients exhibit circannual NMS burden patterns.  
Results: All groups were identical concerning disease onset and duration, HY stage, 
Levodopa equivalent dose, and gender. There was a seasonal difference in NMSS total scores 
(p=0.040), with the highest scores (57.1±42.5) in season 1 (winter months) and the lowest 
(45.1±34.4) in season 3 (summer months) (p=0.037). Seasonal differences were observed in 
NMSS domain 1 (cardiovascular symptoms) (p=0.011), domain 4 (perceptual problems) 
(p=0.017) and domain 9 (miscellaneous symptoms) (p=0.009). A trend was observed for 
domain 2 (sleep) (p=0.057).  
Conclusion: NMS in PD fluctuate throughout the year, with worsening of symptoms in the 
winter months compared to the summer months suggestive of dysfunction of the body’s 
master clock, the suprachiasmatic nuclei. Such variations must be accommodated in daily 
care to ascertain appropriate changes in medication regimes and in clinical trials for the 
interpretation of outcomes. 
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Introduction: 
Diurnal fluctuations in Parkinson disease (PD) are well-recognised, mainly in relation 
to motor symptoms. For example, patterns of daily activity differ significantly between 
patients with PD and healthy elderly people. There is a notable decrease in morning peak 
activity with flattened overall daily activity, both strongly correlating with disease severity 
[1,2]. Responsiveness of motor symptoms to L-dopa treatment also seems to decrease 
throughout the day, without significant alterations in pharmacokinetics, indicating a possible 
circadian system involvement [3,4]. A similarly altered diurnal regulation of non–motor 
symptoms has also been reported for autonomic functions (blood pressure, heart rate), 
psychiatric symptoms (hallucinations) and sleep impairment. Specifically, patients with PD 
may experience a disappearance of circadian rhythmicity in blood pressure regulation 
manifesting with postprandial hypotension, nocturnal hypertension and increased diurnal 
blood pressure variability and decreased hearth rate variability [5-11]. Likewise, 24-hour 
electrocardiography monitoring revealed loss of circadian heart rate variability, a decrease of 
sympathetic activity during the day and lack of sympathetic morning peak increase in heart 
rate as well as a diminished low versus high heart rate frequency ratio reflecting a flattening 
of circadian modulation [12-14]. Moreover, circadian disruption in patients with PD 
experiencing hallucinations is associated with greater intra-daily variability of rest-activity 
cycles, decreased amplitude of activity and increased night-time activity compared to non-
hallucinators [15].  
In clinical practice, we have also observed that the severity of symptoms in PD 
patients may alter with change of seasons. Symptoms appear to be less pronounced when the 
climate is warmer in summer months and worse in winter (when there is also less daylight). 
However, clear evidence for seasonal fluctuations in PD symptoms is lacking, and only a 
handful of studies have explored the possibility of circannual fluctuations in PD. In a study 
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with 546 PD patients, no difference in UPDRS motor scores was observed over the four 
seasons of the year [16]. In another study determining the seasonal effect on hallucinations, 
again no effect of the seasons was observed [17]. For other non-motor symptoms, no studies 
are available. We therefore set out to determine the seasonal effect on non-motor symptoms 
in PD. 
 
Methods: 
In this cross-sectional analysis, all consecutive patients between November 2011 and 
July 2018 with a diagnosis of probable idiopathic PD who participated in the Non-motor 
Longitudinal International Study (NILS) and had a first assessment at King’s College 
Hospital London (NHS Foundation Trust) were included. The NILS Study is the world’s first 
comprehensive study addressing non-motor profiling of PD and the natural history of non-
motor symptoms together with treatment response and clinico-pathological correlations. The 
study involves 14 centres across Europe, but for the current study only patients who had a 
baseline assessment at King’s College Hospital were included. NILS has been adopted as a 
national study by the National Institute of Health Research in the UK (UKCRN No: 10084). 
The study was authorized by local ethics committees (NRES SouthEast London REC3, 
10084, 10/H0808/141). All patients gave written consent prior to study procedures in 
accordance with the Declaration of Helsinki 
 Data extracted from the NILS database concerned sex, disease onset and duration (in 
years), Hoehn and Yahr stage, Levodopa equivalent dose (LEDD) and Non-motor Symptom 
Scale (NMSS), Hospital Anxiety and Depression Scale (HADS), Parkinson Disease Sleep 
Scale (PDSS) and Epworth Sleepiness Scale (ESS) scores. The NMSS addresses NMS that 
have occurred during the previous four weeks [18,19]. We used the following NMSS 
domains: cardiovascular and falls (domain 1), sleep/fatigue (domain 2), mood/cognition 
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(domain 3), perceptual problems/hallucinations (domain 4), attention/memory (domain 5), 
gastrointestinal tract (domain 6), urinary (domain 7), sexual function (domain 8) and 
miscellaneous (domain 9).  
 The date when the NILS baseline assessment took place was recorded. Subsequently, 
patients were then assigned to one of three groups which were defined based on the 
ecological seasons, rather than the classical four seasons. The ecological seasons were 
defined as follows: 1) Prevernal: March and April; 2) Vernal: May – 15 June; 3) Estival: 16 
June – 15 August; 4) Serotinal: 16 August – 15 September; 5) Autumnal: 16 September – 
October and 6) Hibernal: November – February. To obtain an equal distribution across the 
year and to reduce the impact of multiple testing these ecological seasons were merged into 
three groups: 1) winter months: November until February; 2) spring months: March until 15 
June; 3) summer months: 16 June until October. Similar rearrangement methods for seasons 
in order to control for the effect of daytime light duration, by grouping months with similar 
daytime light duration together, have been described before [20].  
The primary outcome was the seasonal difference in NMSS total scores. Secondary 
outcomes were NMSS subscores, PDSS, ESS and HADS scores. For analysis of the 
outcomes we used a one-way analysis of variance (ANOVA). A formal Bonferroni correction 
was used to correct for multiple testing for the secondary outcomes. To test for gender 
differences, Pearson Chi-Square analysis was used. All data was analyzed using SPSS 
Version 24 (IBM SPSS Statistics for Windows, Version 24.0. Armonk, NY: IBM Corp.).  
 
Results: 
A total of 372 patients who had a baseline assessment were included: 107 patients 
were allocated to group 1 (November - February), 107 to group 2 (March - 15 June) and 158 
to group 3 (16 June - October). All groups were identical concerning disease onset and 
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duration, Hoehn and Yahr stage, Levodopa equivalent dose (LEDD), and distribution of sex 
(p>0.10) (table 1). Six patients (1.6%) used antidepressant medication.  
 For the primary outcome, there was a statistically significant group difference with 
high NMS burden (57.1±42.5) in season 1 (November - February) and lower NMS burden 
(45.1±34.4) in season 3 (16 June – October) (one-way ANOVA, p=0.040) (figure 1).  For the 
secondary outcomes, we observed significant seasonal differences in NMSS domain 1 
(cardiovascular and falls; p=0.011), domain 4 (perceptual problems; p=0.017) and domain 9 
(miscellaneous; p=0.009). A trend was observed for domain 2 (sleep and fatigue; p=0.057) 
(Table 1). No difference was observed in the remaining NMSS domains (p > 0.13), nor in 
PDSS, HADS and ESS scores (p>0.19). 
 We performed a separate analysis for domain 9 (miscellaneous) for the separate 
questions in this domain (pain, smell, weight loss and sweating). This revealed that smell was 
better in the summer months (16 June – October) compared to the winter (November – 
February) and spring months (March – 15 June) (p=0.008 and 0.024, respectively; Table 1).  
 
Discussion: 
This is the first comprehensive study showing seasonal differences in NMS in PD 
patients. In line with the subjective impression of patients and health care professionals, we 
observed significant seasonal differences in NMS in PD patients, with mostly higher scores 
(i.e. more complaints) during the winter months and lower scores during the summer months. 
The change of NMS scores between seasons in patients was determined by changes in the 
cardiovascular and falls, hallucinations and perceptual problems and miscellaneous domains 
of the NMSS. A trend was observed for sleep and fatigue. Remarkably, depression scores, 
which could potentially explain these differences, did not carry with the seasons.  
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 Seasonal variations in NMS can be accounted for by several factors. A prime factor is 
the influence of the biological clock located in the suprachiasmatic nuclei (SCN) within the 
hypothalamus. The involvement of the circadian system in PD has been shown in several 
studies. For example, decreased expression of melatonergic receptors (MT1 and MT2) has 
been observed in the amygdala and substantia nigra [23]. In addition, circulating melatonin 
levels are affected in PD patients compared to the healthy elderly population [24,25] and 
these changes correspond with a disruption in slow wave and REM sleep [26]. Here, light 
therapy is a promising strategy to realign circadian output and potentially improve fluctuating 
(both circadian and seasonal) symptoms [27-29].  
 The role of depression, which is known to fluctuate in severity across seasons, being 
worse in winter and autumn compared to the other seasons [30], could explain the 
differences. Depressed patients might be inclined to answer globally more negative to all 
questions. In our study group, however, we did not observe a change in depression scores 
across the different seasons, making it unlikely that fluctuation of depression scores explains 
the seasonal variations in NMS. The absent fluctuation of depressive symptoms might be 
related to the use of the HADS which is normally used as a screening tool and not to make a 
formal diagnosis of depression. In PD, the HADS is not recommended for scoring severity of 
depressive symptoms [31]. Moreover, a recent study has shown that the depression 
subsection of the HADS shows an item bias for several items influencing group differences 
between e.g. age groups [32]. The NMSS is also a global tool for addressing the burden of 
NMS as a while and includes cognition, dysautonomia, sleep and pain and it is likely that 
changes could have been missed in this specific domain because of the composite nature of 
this scale [18,19]. 
 The main limitation of the current study relates to the cross-sectional nature (use of 
single measurements in individual patients), rather than follow-up scores at different times 
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during the year within individual patients. Preferably, a similar study should be conducted 
with several assessments throughout the year within the same patients. We feel, however, that 
our current results are still meaningful, considering there was no difference between the three 
groups concerning disease duration, Hoehn and Yahr stages, LEDD and sex which in 
themselves can also influence NMS burden. It is therefore likely that the observed results are 
indeed due to seasonal changes.   
In conclusion, we observed seasonal differences in total NMS scores in PD patients – 
with highest scores during the winter months and lower scores during the summer months. 
These changes might be explained by altered circannual regulation in PD due to pathology of 
the body’s master clock, as was shown in previous studies. The current results should be 
replicated in further prospective cohorts, with analyses preferably aimed at repeated 
measurements in patients for longer periods of time. The seasonal variation of NMS in PD 
need to be taken into account to ascertain appropriate changes in medication regimes. Also, 
adjustment for cyclical variation of NMS could be important in the interpretation of clinical 
trials. 
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Table 1. Demographics and seasonal variations for Non-motor Symptom Scale (NMSS) 
scores and other non-motor symptoms. LEDD: levodopa equivalent dose; NMSS: non-
motor symptom scale; HADS: hospital anxiety and depression scale; PDSS: Parkinson’s 
disease sleep scale; ESS: Epworth sleepiness scale; M: male; F: female; a: Pearson Chi-
Square test. All statistical analyses were performed using one-way ANOVA. Domain 1: 
cardiovascular and falls; domain 2: sleep/fatigue; domain 3: mood/cognition; domain 4: 
perceptual problems/hallucinations; domain 5: attention/memory; domain 6: gastrointestinal 
tract; domain 7: urinary; domain 8: sexual function; domain 9: miscellaneous. 
 
Figure 1. Non-motor symptom scales (NMSS) total scores grouped according to three 
parts of the year. Group 1: patients assessed in November through February (winter 
months); group 2: patients assessed in March through 15 June (spring months); and group 3: 
patients assessed in 16 June through October (summer months).  
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 Group 1 (Nov-
Feb) 
(n=107) 
Group 2 (Mar-15 
Jun) (n=107) 
Group 3 (16 Jun-Oct) 
(n=158) 
p Post-hoc analysis 
Demographics 
Onset (years) 57.8 (12.1) 58.4 (11.7) 58.3 (11.8) 0.91 - 
Duration (years) 6.7 (6.2) 5.2 (4.9) 5.4 (5.1) 0.10 - 
Hoehn & Yahr 2.3 (0.9) 2.4 (1.0) 2.3 (0.9) 0.49 - 
Sex (M/F) 68/39 (64% M) 71/36 (66% M) 110/48 (70% M) 0.58 - 
LEDD 644.0 (552.8) 521.8 (421.3) 596.0 (506.9) 0.20 - 
NMSS total 
Domain 1 
Domain 2 
Domain 3 
Domain 4  
Domain 5  
Domain 6 
Domain 7 
Domain 8 
Domain 9 
   Pain 
   Smell 
   Weight loss 
   Sweating 
57.1 (42.5) 
2.7 (3.8) 
12.2 (10.3) 
10.0 (13.9) 
2.0 (4.2) 
5.5 (7.0) 
4.6 (5.5) 
8.7 (9.4) 
2.9 (5.9) 
8.5 (8.1) 
2.2 (3.4) 
3.7 (4.3) 
1.2 (2.9) 
1.4 (3.2) 
50.7 (38.2) 
2.2 (3.1) 
9.5 (9.0) 
9.7 (12.4) 
1.3 (3.0) 
5.1 (6.1) 
4.6 (5.7) 
6.4 (8.1) 
2.9 (4.8) 
9.0 (7.7) 
2.7 (3.8) 
4.0 (4.4) 
0.6 (1.8) 
1.7 (3.4) 
45.1 (34.4) 
1.5 (2.7) 
9.7 (9.0) 
7.6 (11.3) 
3.1 (2.4) 
4.6 (6.4) 
4.4 (5.7) 
7.7 (9.3) 
2.4 (5.0) 
6.3 (7.1) 
2.0 (3.3) 
2.3 (3.5) 
0.9 (2.4) 
1.0 (2.5) 
0.040 
0.011 
0.057 
0.21 
0.017 
0.54 
0.95 
0.17 
0.65 
0.009 
0.25 
0.002 
0.13 
0.19 
0.035 (season 1-3) 
0.009 (season 1-3) 
- 
- 
0.014 (season 1-3) 
- 
- 
- 
- 
0.015 (season 2-3) 
- 
0.024 (season 1-3) and 0.004 (season 2-3) 
- 
- 
HADS 
   Depression  
   Anxiety 
11.5 (6.6) 
6.0 (3.8) 
5.5 (3.6) 
12.8 (7.4) 
6.6 (4.3) 
6.1 (4.0) 
11.8 (7.1) 
6.4 (4.3) 
5.4 (3.9) 
0.40 
0.62 
0.28 
- 
- 
- 
PDSS 103.0 (27.8) 104.8 (28.4) 106.4 (27.2) 0.61 - 
ESS 8.3 (5.4) 8.5 (5.6) 7.3 (4.8) 0.19 - 
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Highlights:  
• Non-motor symptoms in Parkinson’s disease show a circannual fluctuation  
• Largest variation was present in cardiovascular, sleep, and hallucinations domains 
• These changes did not coincide with the amount of dopaminergic medication 
 
